

Dasatinib enhances curcumin-induced cytotoxicity, apoptosis and protective autophagy in human schwannoma cells HEI-193: The role of Akt/mTOR/p70S6K signalling pathway

PENGFEI PANG
SHIRONG ZHANG*

*Department of Neurosurgery
The Affiliated Hospital of Northwest
University*

*Xi'an No.3 Hospital, Xi'an, Shaanxi
China, 710000*

ABSTRACT

The present study was carried out in human schwannoma cells (HEI-193) to determine the combined anti-cancer effect of curcumin and dasatinib. Cells were treated with curcumin only, dasatinib only, or the combination of curcumin and dasatinib for 24 hours. Cellular toxicity, cell proliferation, and cell death were determined by LDH, MTT, and trypan blue dye assays, respectively. ELISA based kit was used to determine apoptotic cell death. Western blotting was used to determine the expression of apoptotic and autophagy-associated protein markers. Similarly, expression levels of Akt/mTOR/p70S6K signalling pathway-related proteins were studied using Western blotting. Cell death and apoptosis were significantly higher in HEI-193 cells treated with curcumin and dasatinib combination compared to individual controls. The combination of curcumin and dasatinib significantly enhances autophagy markers compared to individual controls. Furthermore, the combination of curcumin and dasatinib significantly activates Akt/mTOR/p70S6K signalling pathway compared to individual controls. In conclusion, our results suggest that the combination of curcumin and dasatinib significantly enhances cytotoxicity, apoptosis, and protective autophagy in HEI-193 cells through Akt/mTOR/p70S6K signalling pathway.

Keywords: human schwannoma cells, curcumin, dasatinib, cell apoptosis, autophagy

Accepted October 18, 2021
Published online October 19, 2021

INTRODUCTION

Multi-targeted drugs are supposed to replace therapies aiming at a single target (1). Modulating multiple targets is hypothesized to be a golden formula in treating several disorders. The combinatorial therapeutic approach has been successfully applied for the amelioration of several diseases like cancers, malaria *etc.* Combination therapy has been reported to show enhanced antitumour activity in certain cancers (2, 3).

* Correspondence; e-mail: ppf8646812@163.com

Curcumin is a well-known antitumor and anti-inflammatory agent used to treat a wide variety of human diseases, including cancer (4, 5). Curcumin (orally administered) has been reported to stabilize tumour growth in pancreatic cancer patients (6). However, it should be noted here that curcumin has both pro-oxidant and antioxidant properties and therefore, its action is dependent on disease type, curcumin concentration, and immune system of the host (7, 8). Curcumin is reported to target a wide variety of biomolecules like growth regulators, signalling molecules, transcription factors, tumour- and apoptosis-related genes, and adhesion molecules (5, 9). Molecular alterations associated with the curcumin include Akt/mTOR/p70S6K pathway inhibition, overexpression of caspases 3 and 8, NF- κ B inhibition, Bcl-2 down-regulation, COX-2 downregulation and Bax up-regulation (10–12). Curcumin is known to target some cancer-related pathways and has, therefore, been used to target cell apoptosis and survival pathways in many cancer cells. Earlier, curcumin has been reported to up-regulate hsp70 expression to avoid apoptotic death (13). Incubation of curcumin together with heat shock protein inhibitor (KNK437) has been found to significantly suppress the growth of the human schwannoma cell line (HEI-193) (14).

Dasatinib (BMS-354825), a multi-targeted tyrosine kinase inhibitor, was developed for use against imatinib-resistant leukaemias with much higher potency against cells expressing wild-type BCR-ABL (15). Dasatinib is now being used against different types of tumours (16, 17). However, some data suggest its osteoblastogenesis enhancing effect from mesenchymal progenitors (18). Low dasatinib concentrations have been observed to enhance the differentiation and function of mesenchymal osteoprogenitors. The present work aims to explore the protective role of curcumin in combination with dasatinib in HEI-193 cells.

Autophagy plays an important role in the development and progression of cancer by causing the self-degradation of damaged organelles as well as proteins (19, 20). Autophagy performs dual effects on cancer and can either suppress or enhance a tumour (21). It has been reported that cellular integrity is preserved by autophagy and therefore prevents tumour formation. Cells deficient in autophagy are more likely to form a tumour *in vivo*. On the other hand, by allowing cellular survival and suppressing apoptosis, autophagy maintains oncogenesis. Natural agents with anti-tumour activities are known to enhance autophagy in various types of cancers (22–24). However, the exact molecular mechanism by which natural agents induce autophagy-associated cell death in cancers is still unknown.

Akt (serine/threonine-specific protein kinase) has emerged as an important player in the survival, proliferation, and migration of cancer cells (25, 26). Increased activation of Akt has not only been reported as a marker for tumour growth, tumorigenesis and metastasis but also for cancer therapy resistance (27). It has been found that Akt/mTOR/p70S6K signalling regulates apoptosis and autophagy in chemo-resistant cells (28). Inhibition of the PI3K/AKT signalling pathway has been found to restore the sensitivity of colon cancer cells towards 5-fluorouracil (5-FU) (29). Furthermore, inhibiting AKT phosphorylation in prostate cancer cells prevents their metastasis potential (30).

EXPERIMENTAL

Chemicals

Cell culture reagents were purchased from Sigma-Aldrich (USA). Dasatinib (Selleck Chemicals, USA, GmbH: BMS-354825) purity $\geq 99\%$ HPLC) and curcumin (CAS No.: 458-37-7,

purity $\geq 94\%$) from Sigma were prepared in DMSO. A final concentration of $0.01\ \mu\text{mol L}^{-1}$ (dasatinib) and $18\ \mu\text{mol L}^{-1}$ (curcumin) was used for carrying out all the experiments. MTT assay kit, LDH leakage assay kit and Trypan blue assay kit were all purchased from Abcam (USA). Halt Protease Inhibitor Cocktail was obtained from Thermo Scientific (USA). All other chemicals were purchased from Sigma-Aldrich.

Cell culture and treatments

Human schwannoma cells HEI-193 (31) were grown and maintained in DMEM-F12 media plus 10 % fetal bovine serum at $37\ ^\circ\text{C}$ and 5 % CO_2 . Cells were grown in culture media for 24 h and treated with curcumin alone ($18\ \mu\text{mol L}^{-1}$), dasatinib alone ($0.01\ \mu\text{mol L}^{-1}$) or curcumin and dasatinib together for 24 h.

MTT assay

HEI-193 cells (1×10^3) were cultured in 96-well plates for 24 h and treated with curcumin alone ($18\ \mu\text{mol L}^{-1}$), dasatinib alone ($0.01\ \mu\text{mol L}^{-1}$) or curcumin and dasatinib together for 24 h. The percentage of cell proliferation was taken as an average of the results of triplicates.

LDH leakage assay

HEI-193 cells (1×10^3) were cultured in 96-well plates for 24 h and treated with curcumin alone, dasatinib alone ($0.01\ \mu\text{mol L}^{-1}$) or curcumin and dasatinib together for 24 h. For LDH activity analysis, $300\ \mu\text{L}$ of the medium was taken out and analysed using CyQUANT™ LDH Cytotoxicity Assay Kit (Invitrogen, USA).

Trypan blue assay

HEI-193 cells (1×10^3) were cultured in 96-well plates for 24 h and treated with curcumin alone, dasatinib alone ($0.01\ \mu\text{mol L}^{-1}$) or curcumin and dasatinib together for 24 h. For the analysis of trypan blue assay, 0.4 % trypan blue dye was used to determine cell viability. Dead cells take up the dye and can be counted using a haemocytometer, whereas viable cells exclude the dye.

Apoptotic assay

To carry out the apoptotic assay, cells were cultured in 96-well plates for 24 h HEI-193 cells (1×10^3) were cultured in 96-well plates for 24 h and treated with curcumin alone, dasatinib alone ($0.01\ \mu\text{mol L}^{-1}$) or curcumin and dasatinib together for 24 h. ELISA-based In Situ Cell Death Detection Kit (Roche Molecular Biochemicals, USA) was used to determine apoptosis.

Protein extraction

Preparation of HEI-193 cell lysate was achieved using lysis buffer (NP-40). To prevent proteolysis of cell lysate, Halt Protease Inhibitor Cocktail was used. Centrifugation (3000 rpm

for 10 min) of cell lysate was performed to obtain supernatant. Bradford assay was used to determine protein concentration. The preparation of protein samples was carried out as performed by Waza *et al.* (32).

Western blotting

For immunoblotting purposes, proteins were separated on SDS–PAGE and transferred to the PVDF membrane. Detection of target proteins was determined using primary antibodies; anti-Bax, anti-Bcl-2, anti-caspase-3, anti-caspase-9, anti-LC3, anti-Becn1, anti-Atg7, anti-Atg12-Atg5, anti-p-Akt, anti-Akt, anti-p-mTOR, anti-mTOR, anti-p70S6K, anti-p-p70S6K and anti-GAPDH. Primary antibodies were incubated with the membrane overnight. The membranes were rinsed and further incubated with secondary HRP (horseradish peroxidase)-conjugated antibodies. Detection and quantitative analysis of the antibodies were performed with a gel image processing system.

Statistical analysis

SPSS software was used to carry out statistical analysis. Experimental values were given as mean and standard error of the mean. Statistical significance was measured with ANOVA, and for multiple comparisons, post-hoc test was used ($p < 0.05$ as statistically significant).

RESULTS AND DISCUSSION

Effect of curcumin and dasatinib on cellular toxicity

The combination therapies own the main advantage of reduced development of drug resistance and hence enhanced efficacy (2). Moreover, combination therapies also possess the advantages of a lower rate of treatment failure and less fatality (33). Curcumin has been reported to possess anticancer properties with minimal toxicities against normal cells (34, 35). On the other hand, dasatinib was primarily used against imatinib-resistant leukaemias and is now being used against various types of tumours (36, 37). The present study aims to study the combined role of curcumin and dasatinib against HEI-193 cells. Herein, we report that the combination of curcumin and dasatinib increases lactate dehydrogenase (LDH) leakage and cell death in HEI-193 cells.

LDH is found in cells and is responsible for cellular respiration. Breackage of plasma membrane causes LDH release from the cells to outside medium. In cell culture experiments, the presence of LDH in the culture medium represents cell death.

Treatment with curcumin resulted in membrane damage in HEI-193 cells as determined by LDH release. However, curcumin together with dasatinib treatment increased LDH leakage more than the individual treatments as shown in Table I.

HEI-193 cell proliferation and cell death were measured using MTT assay and trypan blue assay, respectively. Curcumin treatment decreases cell viability. However, curcumin, together with dasatinib, significantly decreased cell viability. Similarly, curcumin treatment increased cell death. However, curcumin together with dasatinib treatment significantly increased cell death, as shown in Table I.

Table I. Cell viability and death of HEI-193 cells with different treatments

Samples	LDH assay (% cell death compared to control)	Trypan blue dye uptake (% cell death)	MTT assay (% cell proliferation)
Control (cells only)	100	2.7 ± 1.3	100
Curcumin	115.2 ± 3.1	13.1 ± 2.7	72 ± 3.3
Dasatinib	110.4 ± 2.7	11.7 ± 1.9	84 ± 2.7
Curcumin + dasatinib	130.5 ± 4.7	15.7 ± 3.1	66 ± 4.7




Fig. 1. Individual treatments of cells with curcumin, dasatinib and curcumin/dasatinib combination (control – untreated cells).

Effect of curcumin and dasatinib on apoptotic cell death

The apoptotic assay was carried out by using Cell Death Detection ELISA method. During apoptosis, cells exclude fragmented DNA and histone from the nucleus to the cytoplasm. ELISA based method can be used to detect the excluded DNA and histone in the cytoplasm. We found that individual treatments with curcumin and dasatinib significantly ($p < 0.05$) increased cell apoptosis compared to the control (Fig. 1). However, curcumin in combination with dasatinib showed a significant ($p < 0.05$) increase in apoptosis compared with each of them separately.

Effect of curcumin and dasatinib on the expression of apoptotic markers

Cell survival and death are mainly decided by pro- and anti-apoptotic proteins (38). Protein levels of caspases (pro-apoptotic proteins) are known to be up-regulated during cell death (38). On the other hand, protein levels of anti-apoptotic proteins are down-regulated during cell death (39). We observed a significant increase in the expression levels of pro-apoptotic proteins like caspase-3 and caspase-9 expression during combined treatment of curcumin and dasatinib compared to individual treatments (Fig. 2). Similarly, the combination of curcumin and dasatinib significantly decreased expression levels of anti-apoptotic proteins like Bcl-2, while the expression levels of Bax were increased compared to individual treatments.




Fig. 2. a) Expression analysis of pro-apoptotic and anti-apoptotic proteins using immunoblotting (untreated cells – control; GAPDH – internal control), b) densitometry analysis.

To detect the underlying mechanism of cell apoptosis in HEI-193 cells, Western blotting was carried out. Expression levels of Bcl-2 got decreased by individual treatments with curcumin and dasatinib compared to control (untreated cells). However, the combination of curcumin and dasatinib was more effective in decreasing the Bcl-2 expression compared to the individual treatments. Bax expression levels were increased by individual treatments of curcumin and dasatinib compared to the control. However, the combination of curcumin and dasatinib significantly increased Bax expression compared to individual treatments. Similarly, caspase-3 and caspase-9 expression was increased by individual treatments with curcumin and dasatinib compared to control. However, the combination of curcumin and dasatinib significantly increased caspase-3 and caspase-9 expression compared to individual treatments.

Effect of curcumin and dasatinib on the expression of proteins related to autophagy

Autophagy has been reported to allow cell survival and therefore, promote tumour growth. Different natural agents are known to enhance autophagy in various types of cancers (22). Increased autophagy causes cell death *via* self-digestion and degrades cellular organelles and proteins (40). Microtubule-associated protein light chain 3 (LC3) II is an autophagy-related factor that has been widely studied as an autophagic protein (41). LC3II serves an important role in the development of autophagosomes and their maturation and is therefore used to monitor the autophagic activity in cells (42). Previous studies have demonstrated that curcumin-induced activation of autophagy via promotion of mTOR and LC3 II expression (43).

We set out an experiment to investigate the effect of the combined treatment of curcumin and dasatinib on autophagy markers in human schwannoma cell HEI-193 cells. We found that the combination of curcumin and dasatinib more significantly increased expression levels of autophagy markers like LC3 I, LC3 II, Beclin1, Atg7 and Atg12-Atg5




Fig. 3. a) and b) Expression analysis of autophagy-related marker proteins using immunoblotting (untreated cells – control; GAPDH – internal control), c) densitometry analysis.

expression compared to individual treatments (Fig. 3). Curcumin has been reported to increase expression levels of LC3 I and LC3 II in breast cancer (44). Similarly, dasatinib was reported to increase expression levels of LC3 I and LC3 II in ovarian cancer (45). We observed increased levels of LC3 I and LC3 II after individual treatment with curcumin and dasatinib in HEI-193 cells compared to control. However, the combination of curcumin and dasatinib significantly increases LC3 I and LC3 II expression compared to individual treatments. Similarly, increased protein expression levels of Beclin1, Atg7 and Atg12-Atg5 were observed after individual treatments with curcumin and dasatinib compared to control (untreated cells). However, the combination of curcumin and dasatinib significantly increases Beclin1, Atg7 and Atg12-Atg5 expression compared to individual treatments.

Effect of curcumin and dasatinib on Akt/mTOR/p70S6K signalling pathway

Akt/mTOR/p70S6K signalling pathway has been linked to both apoptosis and autophagy (46, 47). It has been reported that D6 (a curcumin analogue), possesses antiproliferative properties in melanoma partially due to the downregulation of the PI3K/AKT pathway (48). PI3K/AKT/mTOR/P70S6K pathway is considered a critical intracellular signalling pathway for cell survival and death (49). It has been reported that dasatinib induced Src inhibition, which further suppressed the activation of mTOR via the PI3K-Akt signalling pathway in NSCLC Cells (50). Furthermore, the combination of dasatinib and rapamycin was found to induce cell migration and invasion inhibition by suppressing Src/PI3K/AKT signalling (50).




Fig. 4. a) Expression analysis of Akt/mTOR/p70S6K signalling pathway-related proteins using immunoblotting (untreated cells – control; GAPDH – internal control), b) densitometry analysis.

We, therefore, started investigating the effect of the combined treatment of curcumin and dasatinib on the Akt/mTOR/p70S6K signalling pathway in HEI-193 cells. The combination of curcumin and dasatinib significantly decreased protein levels of Akt, p-Akt, mTOR, p-mTOR, p70S6K and p-p70S6K compared to individual treatments (Fig. 4).

CONCLUSIONS

Screening drugs that are previously well-known for curing specific diseases and then coming up with new ways to combine their constituent molecules into a single therapeutic agent could represent a new frontier for pharmacology. In the present study, the combination of curcumin and dasatinib was used against human schwannoma cells HEI-193 to look for their possible synergistic anticancer effects. Our results suggest that curcumin combined with dasatinib significantly enhances cytotoxicity, apoptosis and protective autophagy in HEI-193 cells through Akt/mTOR/p70S6K signalling pathway as compared with the individual treatments. We concluded that the combination of curcumin and dasatinib can be a promising combination when considering the future development of a new therapeutic approach for the treatment of human schwannoma, a devastating tumour of the peripheral nervous system, consisting of different cell types, for which the unmet medical need still exists.

Acknowledgments. – The authors are very grateful for the support from the scientific staff of the Department of Neurosurgery, The Affiliated Hospital of Northwest University.

Conflicts of interest. – The authors declare no conflict of interest.

Funding. – This research received no external funding.

Authors contributions. – Conceptualization, methodology and investigation, P. P; analysis, original draft preparation and editing, S. Z. Both the authors have read and agreed to the published version of the manuscript.

REFERENCES

1. R. R. Ramsay, M. R. Popovic-Nikolic, K. Nikolic, E. Uliassi and M. L. Bolognesi, A perspective on multi-target drug discovery and design for complex diseases, *Clin. Transl. Med.* **7**(1) (2018) 3–16; <https://doi.org/10.1186/s40169-017-0181-2>
2. R. B. Mokhtari, T. S. Homayouni, N. Baluch, E. Morgatskaya, S. Kumar, B. Das and H. Yeger, Combination therapy in combating cancer, *Oncotarget* **8**(23) (2017) 38022–38043; <https://doi.org/10.18632/oncotarget.16723>
3. Y. Yamashita-Kashima, S. Iijima, K. Yorozu, K. Furugaki, M. Kurasawa, M. Ohta and K. Fujimoto-Ouchi, Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models, *Clin. Cancer Res.* **17**(15) (2011) 5060–5070; <https://doi.org/10.1158/1078-0432.CCR-10-2927>
4. S. C. Gupta, S. Patchva, W. Koh and B. B. Aggarwal, Discovery of curcumin, a component of golden spice, and its miraculous biological activities, *Clin. Exp. Pharmacol. Physiol.* **39**(3) (2012) 283–299; <https://doi.org/10.1111/j.1440-1681.2011.05648.x>
5. A. Giordano and G. Tommonaro, Curcumin and cancer, *Nutrients* **11**(10) (2019) Article ID 2376 (20 pages); <https://doi.org/10.3390/nu11102376>
6. A. Hosseini and A. Ghorbani, Cancer therapy with phytochemicals: evidence from clinical studies, *Avicenna J. Phytomed.* **5**(2) (2015) 84–97.
7. A. Banerjee, A. Kunwar, B. Mishra and K. I. Priyadarsini, Concentration dependent antioxidant/pro-oxidant activity of curcumin studies from AAPH induced hemolysis of RBCs, *Chemico-biol. Interact.* **174**(2) (2008) 134–139; <https://doi.org/10.1016/j.cbi.2008.05.009>
8. A. G. Miranda-Diaz, A. Garcia-Sanchez and E. G. Cardona-Munoz, Foods with potential prooxidant and antioxidant effects involved in Parkinson's disease, *Oxid. Med. Cell. Long.* (2020) Article ID 6281454 (17 pages); <https://doi.org/10.1155/2020/6281454>
9. H. Zhou, C. S. Beevers and S. Huang, The targets of curcumin, *Curr. Drug Targ.* **12**(3) (2011) 332–347; <https://doi.org/10.2174/138945011794815356>
10. S. M. Johnson, P. Gulhati, I. Arrieta, X. Wang, T. Uchida, T. Gao and B. M. Evers, Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling, *Anticanc. Res.* **29**(8) (2009) 3185–3190.
11. J. A. Bush, K. J. Cheung Jr. and G. Li, Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53, *Exp. Cell Res.* **271**(2) (2001) 305–314; <https://doi.org/10.1006/excr.2001.5381>
12. M. Rivera, Y. Ramos, M. Rodriguez-Valentin, S. Lopez-Acevedo, L. A. Cubano, J. Zou, Q. Zhang, G. Wang and N. M. Boukli, Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells, *PLoS One* **12**(6) (2017) e0179587 (25 pages); <https://doi.org/10.1371/journal.pone.0179587>
13. Y. C. Chen, T. C. Kuo, S. Y. Lin-Shiau and J. K. Lin, Induction of HSP70 gene expression by modulation of Ca²⁺ ion and cellular p53 protein by curcumin in colorectal carcinoma cells, *Mol. Carcinogen.* **17**(4) (1996) 224–234; [https://doi.org/10.1002/\(SICI\)1098-2744\(199612\)17:4<224::AID-MC6>3.0.CO;2-D](https://doi.org/10.1002/(SICI)1098-2744(199612)17:4<224::AID-MC6>3.0.CO;2-D)
14. L. S. Angelo, J. Y. Wu, F. Meng, M. Sun, S. Kopetz, I. E. McCutcheon, J. M. Slopis and R. Kurzrock, Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways, *Mol. Cancer Therap.* **10**(11) (2011) 2094–2103; <https://doi.org/10.1158/1535-7163.MCT-11-0243>
15. S. Nam, A. Williams, A. Vultur, A. List, K. Bhalla, D. Smith, F. Y. Lee and R. Jove, Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells, *Mol. Cancer Therap.* **6**(4) (2007) 1400–1405; <https://doi.org/10.1158/1535-7163.MCT-06-0446>

16. C. Zeng, L. Zhu, X. Jia, Y. Pang, Z. Li, X. Lu, F. Xie, L. Duan and Y. Wang, Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors, *Gastric Cancer* **23**(5) (2020) 837–847; <https://doi.org/10.1007/s10120-020-01069-1>
17. G. E. Konecny, R. Glas, J. Dering, K. Manivong, J. Qi, R. S. Finn, G. R. Yang, K. L. Hong, C. Ginther, B. Winterhoff, G. Gao, J. Brugge and D. J. Slamon, Activity of the multikinase inhibitor dasatinib against ovarian cancer cells, *Brit. J. Cancer* **101**(10) (2009) 1699–1708; <https://doi.org/10.1038/sj.bjc.6605381>
18. Y. C. Lee, C. F. Huang, M. Murshed, K. Chu, J. C. Araujo, X. Ye, B. deCrombrugge, L. Y. Yu-Lee, G. E. Gallick and S. H. Lin, Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts, *Oncogene* **29**(22) (2010) 3196–3207; <https://doi.org/10.1038/onc.2010.73>
19. I. Dikic, T. Johansen and V. Kirkin, Selective autophagy in cancer development and therapy, *Cancer Res.* **70**(9) (2010) 3431–3434; <https://doi.org/10.1158/0008-5472.CAN-09-4027>
20. J. M. Zarzynska, The importance of autophagy regulation in breast cancer development and treatment, *BioMed. Res. Int.* **2014** (2014) Article ID 710345 (9 pages) <https://doi.org/10.1155/2014/710345>
21. L. Galluzzi, F. Pietrocola, J. M. Bravo-San Pedro, R. K. Amaravadi, E. H. Baehrecke, F. Cecconi, P. Codogno, J. Debnath, D. A. Gewirtz, V. Karantza, A. Kimmelman, S. Kumar, B. Levine, M. C. Maiuri, S. J. Martin, J. Penninger, M. Piacentini, D. C. Rubinsztein, H. U. Simon, A. Simonsen, A. M. Thorburn, G. Velasco, K. M. Ryan and G. Kroemer, Autophagy in malignant transformation and cancer progression, *EMBO J.* **34**(7) (2015) 856–858; <https://doi.org/10.15252/embj.201490784>
22. K. Wang, R. Liu, J. Li, J. Mao, Y. Lei, J. Wu, J. Zeng, J. T. Zhang, H. Wu, L. Chen, C. Huang and Y. Wei, Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1 α -mediated signaling, *Autophagy* **7**(9) (2011) 966–978; <https://doi.org/10.4161/auto.79.15863>
23. Y. Lin, K. Wang, C. Hu, L. Lin, S. Qin and X. Cai, Elemene injection induced autophagy protects human hepatoma cancer cells from starvation and undergoing apoptosis, *Evid. Based Compl. Alternat. Med.* **2014** (2014) Article ID 637528 (9 pages); <https://doi.org/10.1155/2014/637528>
24. S. F. Zhang, X. L. Wang, X. Q. Yang and N. Chen, Autophagy-associated targeting pathways of natural products during cancer treatment, *Asian Pacific J. Cancer Prev.* **15**(24) (2014) 10557–10563; <https://doi.org/10.7314/apjcp.2014.15.24.10557>
25. J. S. O'Donnell, D. Massi, M. W. L. Teng and M. Mandala, PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux, *Sem. Cancer Biol.* **48** (2018) 91–103; <https://doi.org/10.1016/j.semcancer.2017.04.015>
26. G. M. Nitulescu, M. Van De Venter, G. Nitulescu, A. Ungurianu, P. Juzenas, Q. Peng, O. T. Oлару, D. Gradinaru, A. Tsatsakis, D. Tsoukalas, D. A. Spandidos and D. Margina, The Akt pathway in oncology therapy and beyond, *Int. J. Oncol.* **53**(6) (2018) 2319–2331; <https://doi.org/10.3892/ijo.2018.4597>
27. K. A. West, S. S. Castillo and P. A. Dennis, Activation of the PI3K/Akt pathway and chemotherapeutic resistance, *Drug Resist. Updat.* **5**(6) (2002) 234–248; [https://doi.org/10.1016/s1368-7646\(02\)00120-6](https://doi.org/10.1016/s1368-7646(02)00120-6)
28. C. H. Chang, C. Y. Lee, C. C. Lu, F. J. Tsai, Y. M. Hsu, J. W. Tsao, Y. N. Juan, H. Y. Chiu, J. S. Yang and C. C. Wang, Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling, *Int. J. Oncol.* **50**(3) (2017) 873–882; <https://doi.org/10.3892/ijo.2017.3866>
29. J. Xu, S. Zhang, R. Wang, X. Wu, L. Zeng and Z. Fu, Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway, *Biosci. Rep.* **37**(3) (2017) Article ID BSR20160447 (10 pages); <https://doi.org/10.1042/BSR20160447>

30. M. J. Hour, S. C. Tsai, H. C. Wu, M. W. Lin, J. G. Chung, J. B. Wu, J. H. Chiang, M. Tsuzuki and J. S. Yang, Antitumor effects of the novel quinazolinone MJ-33: inhibition of metastasis through the MAPK, AKT, NF-kappaB and AP-1 signaling pathways in DU145 human prostate cancer cells, *Int. J. Oncol.* **41**(4) (2012) 1513–1519; <https://doi.org/10.3892/ijo.2012.1560>
31. P. Lepont, J. T. Stickney, L. A. Foster, J. J. Meng, R. F. Hennigan and W. Ip, Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity, *Mutation Res.* **637**(1-2) (2008) 142–151; <https://doi.org/10.1016/j.mrfmmm.2007.07.015>
32. A. A. Waza, K. Andrabi and M. U. Hussain, Protein kinase C (PKC) mediated interaction between connexin43 (Cx43) and K(+)(ATP) channel subunit (Kir6.1) in cardiomyocyte mitochondria: Implications in cytoprotection against hypoxia induced cell apoptosis, *Cell. Signalling* **26**(9) (2014) 1909–1917; <https://doi.org/10.1016/j.cellsig.2014.05.002>
33. R. M. Webster, Combination therapies in oncology, *Nat. Rev. Drug Discov.* **15**(2) (2016) 81–82; <https://doi.org/10.1038/nrd.2016.3>
34. A. M. Alizadeh, M. Sadeghizadeh, F. Najafi, S. K. Ardestani, V. Erfani-Moghadam, M. Khaniki, A. Rezaei, M. Zamani, S. Khodayari, H. Khodayari and M. A. Mohagheghi, Encapsulation of curcumin in diblock copolymer micelles for cancer therapy, *BioMed. Res. Int.* **2015** (2015) Article ID 824746 (15 pages); <https://doi.org/10.1155/2015/824746>
35. R. Chang, L. Sun and T. J. Webster, Short communication: selective cytotoxicity of curcumin on osteosarcoma cells compared to healthy osteoblasts, *Int. J. Nanomed.* **9** (2014) 461–465; <https://doi.org/10.2147/IJN.S55505>
36. G. Wei, S. Rafiyath and D. Liu, First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib, *J. Hematol. Oncol.* **3** (2010) Article ID 47 (10 pages); <https://doi.org/10.1186/1756-8722-3-47>
37. H. Kantarjian, R. Pasquini, V. Levy, S. Jootar, J. Holowiecki, N. Hamerschlak, T. Hughes, E. Bleickardt, D. Dejudin, J. Cortes and N. P. Shah, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R), *Cancer* **115**(18) (2009) 4136–4147; <https://doi.org/10.1002/cncr.24504>
38. T. Bartke, D. Siegmund, N. Peters, M. Reichwein, F. Henkler, P. Scheurich and H. Wajant, p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells, *Oncogene* **20**(5) (2001) 571–580; <https://doi.org/10.1038/sj.onc.1204124>
39. R. S. Wong, Apoptosis in cancer: from pathogenesis to treatment, *J. Exp. Clin. Cancer Res.* **30**(1) (2011) Article ID 87 (14 pages); <https://doi.org/10.1186/1756-9966-30-87>
40. L. Ouyang, Z. Shi, S. Zhao, F. T. Wang, T. T. Zhou, B. Liu and J. K. Bao, Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis, *Cell Prolif.* **45**(6) (2012) 487–498; <https://doi.org/10.1111/j.1365-2184.2012.00845.x>
41. M. B. Schaaf, T. G. Keulers, M. A. Vooijs and K. M. Rouschop, LC3/GABARAP family proteins: Autophagy(un)related functions, *FASEB J.* **30**(12) (2016) 3961–3978; <https://doi.org/10.1096/fj.201600698R>
42. M. S. Dong, S. H. Jung, H. J. Kim, J. R. Kim, L. X. Zhao, E. S. Lee, E. J. Lee, J. B. Yi, N. Lee, Y. B. Cho, W. J. Kwak and Y. I. Park, Structure-related cytotoxicity and anti-hepatofibrotic effect of asiatic acid derivatives in rat hepatic stellate cell-line, HSC-T6, *Arch. Pharm. Res.* **27**(5) (2004) 512–517; <https://doi.org/10.1007/BF02980124>
43. J. Han, X. Y. Pan, Y. Xu, Y. Xiao, Y. An, L. Tie, Y. Pan and X. Li, Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage, *Autophagy* **8**(5) (2012) 812–825; <https://doi.org/10.4161/auto.19471>

44. F. Guan, Y. Ding, Y. Zhang, Y. Zhou, M. Li and C. Wang, Curcumin suppresses proliferation and migration of MDA-MB-231 breast cancer cells through autophagy-dependent Akt degradation, *PLoS ONE* **11**(1) (2016) e0146553; <https://doi.org/10.1371/journal.pone.0146553>
45. X. F. Le, W. Mao, Z. Lu, B. Z. Carter and R. C. Bast, Dasatinib induces autophagic cell death in human ovarian cancer, *Cancer* **116**(21) (2010) 4980–4990; <https://doi.org/10.1002/cncr.25426>
46. H. J. Lee, V. G. V. Saralamma, S. M. Kim, S. E. Ha, S. Raha, W. S. Lee, E. H. Kim, S. J. Lee, J. D. Heo and G. S. Kim, Pectolarigenin induced cell cycle arrest, autophagy, and apoptosis in gastric cancer cell via PI3K/AKT/mTOR signaling pathway, *Nutrients* **10**(8) (2018) Article ID 1043 (15 pages); <https://doi.org/10.3390/nu10081043>
47. K. Y. Kim, K. I. Park, S. H. Kim, S. N. Yu, S. G. Park, Y. W. Kim, Y. K. Seo, J. Y. Ma and S. C. Ahn, Inhibition of autophagy promotes salinomycin-induced apoptosis via reactive oxygen species-mediated PI3K/AKT/mTOR and ERK/p38 MAPK-dependent signaling in human prostate cancer cells, *Int. J. Mol. Sci.* **18**(5) (2017) Article ID 1088 (15 pages); <https://doi.org/10.3390/nu10081043>
48. C. Rozzo, M. Fanciulli, C. Fraumene, A. Corrias, T. Cubeddu, I. Sassu, S. Cossu, V. Nieddu, G. Galleri, E. Azara, M. A. Dettori, D. Fabbri, G. Palmieri and M. Pisano, Molecular changes induced by the curcumin analogue D6 in human melanoma cells, *Mol. Cancer* **12** (2013) Article ID 37 (16 pages); <https://doi.org/10.1186/1476-4598-12-37>
49. C. Porta, C. Paglino and A. Mosca, Targeting PI3K/Akt/mTOR signaling in cancer, *Front. Oncol.* **4** (2014) (11 pages); <https://doi.org/10.3389/fonc.2014.00064>
50. B. Chen, X. Xu, J. Luo, H. Wang and S. Zhou, Rapamycin enhances the anti-cancer effect of dasatinib by suppressing Src/PI3K/mTOR pathway in NSCLC cells, *PLoS ONE* **10**(6) (2015); <https://doi.org/10.1371/journal.pone.0129663>